Danish Pharmacovigilance Update, 17 November 2011

In this issue of Danish Pharmacovigilance Update:

• Domperidone (Motilium® etc.) and potential risk of cardiac disorders
• The European Medicines Agency, EMA, recommends a lower dose of the antidepressant citalopram
• Pradaxa® – new recommendations for assessment of renal function
• Antiepileptics and the risk of bone disorders
• No evidence of causal relationship between treatment with angiotensin II antagonists and increased risk of developing cancer
• Xigris® for treatment of adults with severe sepsis and multiple organ failure to be withdrawn
• Danish Pharmacovigilance Update celebrates 2-year anniversary

Download the newsletter in the box to the right.